Coadministration of Short‐Term Zolpidem with Sertraline in Healthy Women
@article{Allard1999CoadministrationOS, title={Coadministration of Short‐Term Zolpidem with Sertraline in Healthy Women}, author={Stephane E. Allard and Stephen M. Sainati and Barbara Roth-Schechter}, journal={The Journal of Clinical Pharmacology}, year={1999}, volume={39} }
This study was undertaken to determine whether there are pharmacokinetic (PK) interactions between zolpidem, a hypnotic, and sertraline, an antidepressant. Twenty‐eight healthy female volunteers received a single dose of zolpidem alone and five consecutive dose(s) of zolpidem 10 mg in the presence of chronic doses (19 days) of sertraline 50 mg. Using HPLC, plasma levels of zolpidem, sertraline, and N‐desmethylsertraline were determined at different times throughout the study and PK parameters…
22 Citations
Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects.
- Medicine, BiologyArchives of pharmacal research
- 2019
The experimental data demonstrate the significant pharmacokinetic interaction between zolpidem and clarithromycin at steady-state and elimination half-life of zolPidem was 1.40-fold longer during co-administration with clarityromycin and its apparent oral clearance was 36.2% lower with claritromycin administration.
Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
- Psychology, MedicineDrugs
- 2000
Although zolpidem produced some psychomotor and memory impairment over the first few hours after administration, it had few next-day effects and was comparable or superior to flunitrazepam and flurazep am and comparable to other benzodiazepines in patients with insomnia.
Clinical Pharmacokinetics of Sertraline
- Psychology, BiologyClinical pharmacokinetics
- 2002
Sertraline is a naphthalenamine derivative with the predominant pharmacological action of inhibiting presynaptic reuptake of serotonin from the synaptic cleft that is well tolerated in therapeutic dosages and relatively safe in overdosage.
Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives
- BiologyClinical pharmacokinetics
- 2004
While zaleplon may be best indicated for the delayed onset of sleep, zolpidem and zopiclone may be better indicated for maintaining a complete night’s sleep.
Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon
- Medicine, BiologyCNS drugs
- 2003
Few clinically important interactions appear to have been reported in the literature with zaleplon, zolpidem and zopiclone, and the fact that these drugs are newer to the market and have not been as extensively studied as the conventional benzodiazepines may be the reason for this.
Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis
- Medicine, BiologyThe AAPS Journal
- 2020
Study findings indicate that sertraline PK is linear in healthy adult subjects at doses ≥ 50 mg, and exposures were nonlinear only after single oral doses <50 mg likely due to reduced bioavailability.
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A
- Biology, MedicineEuropean Journal of Clinical Pharmacology
- 2009
Zolpidem is a relatively weak mechanism-based inactivator of human CYP3A in vitro, and is unlikely to act as a significant perpetrator of metabolic interactions involving CYP2A drugs.
Sertraline: A Review of its Therapeutic Use in Post-Traumatic Stress Disorder
- Psychology, Medicine
- 2000
Sertraline has demonstrated efficacy in the treatment of PTSD, particularly in female patients and in non-combat-induced PTSD, and is generally well tolerated, and appears to have a lower potential for drug interactions than other SSRIs, although direct comparisons are lacking.
Zolpidem modified-release in insomnia
- Medicine, PsychologyNeuropsychiatric disease and treatment
- 2007
Two double-blind, placebo-controlled, parallel-group trials demonstrated efficacy in adults and elderly patients treated with zolpidem MR for 3 weeks without significant impairment in next-day psychomotor functioning.
Comparative Tolerability of Newer Agents for Insomnia
- Psychology, MedicineDrug safety
- 2009
The adverse event profiles of these newer sedative hypnotics, their effects on memory and psychomotor performance, abuse liability concerns and the most recent information about the rare adverse effects that prompted the recent revision to the labelling of drugs in the hypnotic class are reviewed.
References
SHOWING 1-10 OF 50 REFERENCES
The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics.
- Medicine, PsychologyInternational journal of clinical pharmacology and therapeutics
- 1996
It is concluded that the onset of action of zolpidem may possibly be shortened in the presence of fluoxetine, but no other significant pharmacokinetic or pharmacodynamic interactions occurred.
Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers
- MedicineClinical pharmacokinetics
- 1997
The terminal elimination half-life of sertraline was similar in young females, elderly males and elderly females and the mean steady-state area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC24), but were approximately 25% lower in the young males.
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
- Psychology, MedicineThe Journal of clinical psychiatry
- 1994
10 mg of zolpidem was found to be safe and effective for the long-term treatment of chronic insomnia, demonstrating hypnotic efficacy without affecting sleep stages or producing tolerance effects, rebound effects, or detrimental effects on psychomotor performance.
Pharmacokinetics of selective serotonin reuptake inhibitors.
- Psychology, MedicinePharmacology & therapeutics
- 2000
Retrospective Review of Hypnotic Use in Combination with Fluoxetine or Sertraline
- Psychology, Medicine
- 1995
A high percentage of patients receiving concomitant administration of these agents warrants continued monitoring of the activating effects of fluoxetine and sertraline, the complicating drug-drug interactions, and the costs associated with polypharmacy.
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
- Medicine, BiologyClinical pharmacokinetics
- 1997
An overview of the clinically relevant pharmacology of selective serotonin reuptake inhibitors (SSRIs) with an emphasis on their pharmacokinetics and effects on cytochrome P450 (CYP) enzymes is presented.
Clinical Pharmacokinetics of Antidepressants in the Elderly
- Medicine
- 1993
Much work is still needed to evaluate the relationships among drug concentrations at steady-state, efficacy and adverse effects in the elderly, particularly in the case of tricyclic antidepressants.
Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients.
- Psychology, MedicineThe Journal of clinical psychiatry
- 1990
Sertraline was associated with a statistically lower frequency of somnolence, dry mouth, constipation, ataxia, and pain and a higher frequency of nausea, anorexia, diarrhea/loose stools, and insomnia; thus, anticholinergic effects were less common and gastrointestinal effects were more common with sertralines than with amitriptyline.
A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
- Psychology, MedicineThe Journal of clinical psychiatry
- 1997
While nefazodone and fluoxetine showed equivalent antidepressant efficacy, more objective, subjective, and clinician-rated measures of sleep disturbance were improved during treatment with nefzodone than with fluoxettine.